TAKEDA PHARMACEUTICAL CO LTD

Alpha Score of 37 reflects weak overall profile with moderate momentum, weak value, poor quality. Based on 3 of 4 signals — score is capped at 90 until remaining data ingests.

Takeda Pharmaceutical Company Limited American Depositary Receipt represents ownership in Takeda Pharmaceutical Company Limited, Japan's largest pharmaceutical company. It provides international investors access to the company's ordinary shares, with a ratio of 2 ADSs equaling 1 ordinary share, facilitating dividends converted from Japanese Yen to US Dollars by the depositary bank. The company focuses on researching, developing, manufacturing, and marketing pharmaceutical drugs across five core therapeutic areas: oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which form the majority of its business. Its operations span diverse geographies, including significant presence in the US, Japan, Europe, and Canada, serving global healthcare needs through innovative treatments. Founded in 1781 and headquartered in Tokyo, Japan, Takeda Pharmaceutical Company Limited maintains a strong emphasis on capital allocation for growth and shareholder returns while upholding investment-grade credit ratings.